Frequency of IRB Review; Verification Regarding Material Changes
Written Guidance Document

Purpose: Each IRB must follow written procedures for determining which projects require review more often than annually and which projects need verification from sources other than the investigators that no material changes have occurred since previous IRB review [45 CFR 46.108(3)(ii), 21 CFR 56.108(a)(2)].

Operational Details

1. IRB approval period: The calculation of the approval and expiration dates is as follows:

   1.1 For initial review the date that the research is approved, or if modifications are required (to secure approval), the date that the modifications/conditions are met by the investigator (date of approval) is the “start date” for the approval period.

   1.2 For continuing review the date that the research is re-approved, or if modifications are required (to secure approval), the date that the modifications/conditions are met by the investigator (date of approval) is the “start date” of the re-approval period.

   1.3 The expiration date of convened research, and expedited research when applicable, is the last date of the approval period. Unless the IRB determines an earlier expiration date, the expiration date is one year (minus one day) from the date of approval.

      • For example, the expiration date for research that was approved on June 1, 2019, with a continuing review frequency of one year is May 31, 2020. Therefore, the last date that the research can be performed (unless the study is re-approved) is May 31, 2020.

2. Determining frequency of IRB review: The IRB Member(s)/Committee conducting the initial or continuing review (or as otherwise warranted) will determine continuing review at intervals appropriate to the research, but not less than once per year for convened research. Should the IRB Member(s)/Committee determine that expedited research requires continuing review, the reasons continuing review is required must be clearly documented. An approval period of no more than six months can be granted for Phase I Clinical Trials or research in which there is more than minimal risk involving a vulnerable population with no prospect of direct benefit to the individual participants. Examples of criteria used to make a determination on the frequency of review include, but is not limited to:

   2.1 The nature of the study
   2.2 The risks posed by the study and any minimization of those risks
   2.3 The degree of uncertainty regarding the risks involved
   2.4 The vulnerability of the subject population
   2.5 The experience and qualifications of the research team
   2.6 The projected rate of enrollment
   2.7 Whether the study involves novel therapies
   2.8 Any previous non-compliance or misconduct by the researcher(s)
   2.9 The IRB’s previous experience with the investigator and/or sponsor
   2.10 Unanticipated problems, adverse events, and/or withdrawal of participants

Effective date: 09/12/2019
2.11 For FDA regulated studies, the trial phase assigned by the FDA
2.12 Other criteria as determined by the IRB

3. **Documenting the approval period:** The approval period will be documented in the following locations by HRPP staff:

   3.1 IRB meeting minutes
   3.2 IRB study records
   3.3 IRB approval letter

4. **Communicating the IRB’s determinations regarding the approval period to the researcher(s):** Principal Investigators are notified of the approval period in their IRB approval letter and, as a courtesy, may be reminded of upcoming expirations. It is the Principal Investigator’s responsibility to be aware of and track approval and expiration dates and apply for continuing review in ample time for the IRB review process to be completed (two months prior to expiration is recommended).

5. **Authority to reduce the approval period:** The IRB may reduce the time period of approval at any time during the approval period when warranted based on risk to subjects, investigator non-compliance or misconduct, or any other factor that could jeopardize the health or welfare of a study subject.

6. **Verification of no material changes from other sources other than the investigator:** The IRB will consider whether verification is required from sources other than the investigator that no material changes have occurred since previous IRB review, including the general criteria utilized to make the determination. Examples of when the IRB may require verification from other sources include but is not limited to:

   6.1 Pattern of submitting incorrect versions of required documents
   6.2 History of late reporting of adverse events or unanticipated problems
   6.3 Previous late reporting of changes in research
   6.4 Report from a third party of deviations of approved research procedures
   6.5 Previous non-compliance or misconduct by the researcher(s)
   6.6 Continuing review report indicates changes not previously reported
   6.7 Randomly selected projects
   6.8 Complex projects

Effective date: 09/12/2019